| 000 | 01841 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516133818.0 | ||
| 264 | 0 | _c20130730 | |
| 008 | 201307s 0 0 eng d | ||
| 022 | _a1499-3872 | ||
| 024 | 7 |
_a10.1016/s1499-3872(13)60010-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYan, Bing-Zhu | |
| 245 | 0 | 0 |
_aHepatoprotective effects of cathepsin B inhibitor on acute hepatic failure induced by lipopolysaccharide/D-galactosamine in mice. _h[electronic resource] |
| 260 |
_bHepatobiliary & pancreatic diseases international : HBPD INT _cFeb 2013 |
||
| 300 |
_a80-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCaspases _xmetabolism |
| 650 | 0 | 4 |
_aCathepsin B _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCysteine Proteinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aCytochromes c _xmetabolism |
| 650 | 0 | 4 |
_aDipeptides _xpharmacology |
| 650 | 0 | 4 |
_aGalactosamine _xpharmacology |
| 650 | 0 | 4 | _aIn Situ Nick-End Labeling |
| 650 | 0 | 4 | _aInjections, Intraperitoneal |
| 650 | 0 | 4 |
_aLipopolysaccharides _xpharmacology |
| 650 | 0 | 4 |
_aLiver Failure, Acute _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred Strains |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-2 _xmetabolism |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aTransaminases _xblood |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xblood |
| 700 | 1 | _aChen, Li-Yan | |
| 700 | 1 | _aKang, Lan | |
| 700 | 1 | _aWang, Xiao-Ren | |
| 700 | 1 | _aBi, Man-Ru | |
| 700 | 1 | _aWang, Wei | |
| 700 | 1 | _aYang, Bao-Shan | |
| 773 | 0 |
_tHepatobiliary & pancreatic diseases international : HBPD INT _gvol. 12 _gno. 1 _gp. 80-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s1499-3872(13)60010-7 _zAvailable from publisher's website |
| 999 |
_c22488327 _d22488327 |
||